Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock—Adaptive Clinical Trial
Roger Lewis(University of California, Los Angeles), Scott Berry(Queen's University), Steven M. Opal(Brown University), Peter Pickkers(Radboud University Nijmegen), Allan Blemings(Ferring Pharmaceuticals (Denmark)), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Egbert van der Meulen(Ferring Pharmaceuticals (Denmark)), Todd Graves(Abington Memorial Hospital), Bruno François(Inserm), Karsten Jacobsen(Ferring Pharmaceuticals (Denmark)), James A. Russell(University of British Columbia), Donald M. Yealy(University of Pittsburgh), Jan E. Carlsen, Anne Louise Kjølbye(Ferring Pharmaceuticals (Denmark)), Derek C. Angus(University of Pittsburgh), Nis A. Windeløv(Ferring Pharmaceuticals (Denmark)), Anders Perner(Unknown)
Cited by 44
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k